High-level penicillin resistance has been associated with treatment failure in patients with Streptococcus pneumoniae infections. To identify a subgroup of patients at low risk for high-level penicillin-nonsusceptible S. pneumoniae bacteremia, a cross-sectional study of 303 patients was performed. For the total study population, penicillin resistance was observed in 98 (32%) of 303 patients; high-level resistance was seen in 33 (11%). A predictive model was created by using 3 baseline variables that were independently associated with high-level penicillin resistance: previous b-lactam antibiotic use, previous stay in a risk area (defined as stay in day care facilities, prisons, homeless shelters, nursing homes, or other long-term care facilities), and previous respiratory tract infection. The model was used to identify patients at low and high risk for high-level penicillin-resistant pneumococcal bacteremia. None of the isolates of patients in the low-risk subgroup had ceftriaxone resistance. Patients in the low-risk subgroup could be empirically treated with fluoroquinolone-sparing regimens.
The excellent activity of the new fluoroquinolones (i.e., levofloxacin, gatifloxacin, and moxifloxacin) against PNSP and the convenient dosing schedule have fostered their use in the empirical treatment of patients with community-acquired pneumonia [10] . Alarmingly, recent reports describe an increasing trend in the number of pneumococcal isolates with reduced susceptibility to fluoroquinolones [11] [12] [13] [14] [15] . Cases of treatment failures in pneumococcal pneumonia caused by fluoroquinolonenonsusceptible isolates have emphasized the potential clinical importance of this emerging problem [16] . Several guidelines for the treatment of patients with pneumonia advocate avoiding the use of the new fluoroquinolones in patients who are not at risk for having PNSP infection [17] [18] [19] . The use of alternative agents (i.e., b-lactams and/or macrolides) in patients at low risk of having PNSP infection would reduce the use of fluoroquinolones and might delay the emergence of fluoroquinolone-nonsusceptible pneumococcal isolates. To our knowledge, we have conducted the first study to determine independent risk factors specific for high-level PNSP bacteremia and to identify a subgroup of patients at low risk of having PNSP bacteremia. 
PATIENTS, MATERIALS, AND METHODS

Setting.
We conducted a cross-sectional study by using retrospective data on 303 children and adults who presented with S. pneumoniae bacteremia to 4 tertiary care hospitals in New Orleans, Louisiana, during the period of January 1996 through October 2001. Charity Hospital and University Hospital of the Medical Center of Louisiana at New Orleans provide service for an urban indigent population. Tulane University Hospital and Clinic mainly provides medical services for the insured population in New Orleans, and the Veterans Affairs Medical Center mainly serves the veteran population in the southeast Louisiana area.
Study design.
Patients with pneumococcal bacteremia were identified by reviewing the clinical microbiology laboratory blood culture records at the 4 hospitals. Bacteremia was defined as isolation of S. pneumoniae from у1 blood culture bottle (aerobic and/or anaerobic bottle) in the presence of clinical features consistent with infection or sepsis [20] . All patients with у1 positive blood culture result obtained within 14 days of the initial positive blood culture result were included and were counted as having 1 bacteremic episode. If a patient had 11 episode of pneumococcal bacteremia within the time of observation, only the first episode was included in the study. Nosocomial acquisition was defined as bacteremia first occurring 148 h after admission. The term "previous respiratory infection" included patients who had a documented history of previous upper or lower respiratory infections in the previous 12 months.
Pneumococcal isolates were screened for penicillin resistance by use of the oxacillin disk test and classified as penicillin susceptible (MIC, р0.06 mg/mL), intermediate-level penicillin nonsusceptible (MIC, 0.12-1 mg/mL), and high-level penicillin nonsusceptible (MIC, у2 mg/mL) by use of the Etest methodology (AB Biodisk). Furthermore, all penicillin-susceptible and intermediate-level PNSP (MIC, р1 mg/mL) were classified as "penicillin-susceptible/intermediate-level penicillin-nonsusceptible S. pneumoniae" (PSISP). The outcome of the study was high-level PNSP bacteremia (MIC, у2 mg/mL). Isolates were also tested for ceftriaxone susceptibility and classified on the basis of the new interpretive criteria for nonmeningeal isolates: drug MICs of р1, 2, and у4 mg/mL for susceptible, intermediate, and resistant isolates, respectively [21, 22] .
Baseline sociodemographic and clinical data were recorded by reviewing all inpatient, clinic, and emergency department records and by review of computerized inpatient and outpatient pharmacy records at all 4 hospitals. A predesigned, standardized data extraction instrument was used for data recording. Patients were excluded if not all existing medical records from the 6-month period before the first positive blood culture result were available. The study was approved by the Tulane University Committee on Use of Human Subjects.
Data abstraction. The following data were recorded from the medical records: sociodemographic information, comorbid conditions, immunocompetence, previous respiratory tract infections and hospitalizations, stay in a risk area (defined as stay in day care facilities, prisons, homeless shelters, nursing homes, or other long-term care facilities), and primary source of bacteremia. The latter was based on the reported clinical assessment of the patient's primary physician and differentiated into the following categories: pneumonia, otitis media, meningitis, infective endocarditis, skin/soft-tissue infection, unknown source of infection, or other source of infection. Comorbidity was assessed with the Charlson comorbidity scale [23] .
A detailed history of antibiotic use within the previous 6 months was obtained. Antibiotics were classified as b-lactams (penicillin/penicillin derivatives and cephalosporins), sulfonamides, macrolides, and fluoroquinolones. Any dose, including a single administration of the antibiotic, was deemed to be significant and was recorded.
Statistical analysis. Bivariate analysis was conducted by Pearson's x 2 test or Fisher's exact test to identify factors that were significantly associated with the outcome of high-level penicillin-resistant pneumococcal bacteremia ( ). The P ! .05 Wilcoxon rank sum test was used to detect differences in patients' median age. Multivariate analysis with backward stepwise logistic regression was performed to identify independent risk factors. All variables for which P was !.2 on bivariate analysis were evaluated in the logistic model to avoid exclusion of potentially significant variables. Sensitivity, specificity, and positive and negative predictive values were calculated. The likelihood ratio for a positive test result was defined as the ratio of the sensitivity divided by the false-positive error rate; and the likelihood ratio for a negative test result was defined as the ratio of the false-negative error rate divided by the specificity. A concordance index (c-index), equal to the area under the curve for logistic regression, was calculated to assess the accuracy of the model for discrimination of patients at risk for high-level penicillin resistance [24] . Bootstrapping was performed to estimate the internal validity of the regression model. All statistical analyses were conducted using SPSS for Windows software, version 11.0 (SPSS).
RESULTS
A total of 447 episodes of S. pneumoniae bacteremia were identified by review of microbiological records at the 4 hospitals for the period of January 1996 through October 2001. Of these, 144 episodes were excluded for the following reasons: incomplete medical records ( ), penicillin susceptibility testing n p 121 of the pneumococcal isolate was not performed by the laboratory ( ), or the same patient had 11 episode of S. n p 17 pneumoniae bacteremia within the study period ( ). A total n p 6 ), and previous respiratory infection (adjusted P p .004 OR, 5.0; 95% CI, 1.6-15.6; ) were associated with the P p .005 occurrence of PNSP bacteremia (table 3). Calculation of the accuracy of the prediction by using the c-index showed a value of 0.87 (95% CI, 0.81-0.92). Because the lower border of the 95% CI was 10.5, the model predicted the occurrence of the outcome of interest significantly better than chance alone. The values of both the adjusted ORs and the c-index were very similar in the bootstrap model, which is consistent with a good prediction capacity of the model.
Cross-resistance to third-generation cephalosporins. Data on susceptibility to third-generation cephalosporins were available for 265 pneumococcal isolates (87%) (table 4). All PSISP isolates were also susceptible to ceftriaxone. Among 28 PNSP isolates that were also tested for third-generation cephalosporin susceptibilities, 15 (54%) were susceptible to ceftriaxone, 11 (39%) were intermediate-level nonsusceptible, and 2 (7%) were high-level nonsusceptible, according to the new guidelines for nonmeningeal isolates. When these 13 latter isolates were compared with the 252 isolates that were fully susceptible to ceftriaxone, the 3 independent risk factors for PNSP bacteremia were also highly significantly associated with third-generation cephalosporin resistance on bivariate analysis ( ; data P ! .001 not shown).
Identification of a low-risk subgroup for PNSP bacteremia. Table 5 classifies patients with pneumococcal bacteremia into low-risk and a high-risk subgroups for high-level penicillin resistance according to the presence of none versus у1 independent factor (previous b-lactam use, institutionalization/stay in risk area, and previous respiratory infection). Patients in the low-risk subgroup had none of the aforementioned predictors; patients in the high-risk subgroup had у1 risk factor. This clinical model to predict a high risk of infection with PNSP had a sensitivity of 97% (32 of 33) and a negative predictive value of 99% (152 of 153). Specificity and positive predictive value were 56% (152 of 270) and 21% (32 of 150), respectively. The positive and the negative likelihood ratios were 2.2 and 0.05, respectively.
DISCUSSION
Penicillin-resistant S. pneumoniae has emerged as a worldwide problem in the past decade. In the United States, penicillin resistance in S. pneumoniae has been observed in up to 34% of all isolates [25] . This is very similar to the prevalence of penicillin resistance in our study (33%). One-third (33 of 98) of these resistant isolates had high-level penicillin-nonsusceptibility. Multiple logistic regression analysis showed that previous b-lactam use, previous stay in a risk area, and previous respiratory infection were independently associated with PNSP bacteremia ( ).
The clinical significance of penicillin resistance for the treatment of pneumococcal infections remains controversial. Many studies have reported no adverse impact on clinical outcome for nonmeningeal infections caused by penicillin-resistant organisms. However, the number of cases with high-level resistant isolates were low in these studies, thus limiting the power to detect a significant difference [6, 17] . Several recent studies of patients with pneumococcal pneumonia have shown a significant association ( ) between high-level resistant S. pneu-P ! .05 moniae isolates and adverse clinical outcomes. Turett et al. [7] found high-level penicillin-resistance to be an independent risk factor of mortality among 432 patients who presented with bacteremic pneumonia to the Bronx-Lebanon Hospital Center. In a large study by Feikin et al. [8] , the mortality rate was significantly increased among patients with highly nonsusceptible (MIC, у4 mg/mL) pneumococcal pneumonia after exclusion of deaths occurring within the first 4 days after hospital admission. Metlay et al. [9] reported a higher rate of suppurative complications among patients with nonsusceptible pneumococcal pneumonia. These results differ from those of a recent large international study by Yu et al. [26] who did not find any association between penicillin-resistant pneumococcal bacteremia and increased mortality. Unlike our study, they included intermediate-level nonsusceptibility into their definition of a penicillin-resistant isolate. The results of these studies, including our study, do not apply to patients with pneumococcal meningitis, with or without bacteremia, for which intermediate-level penicillin resistance has been associated with treatment failure [27] .
Several guidelines for the treatment of patients with pneumonia advocate the use of the new fluoroquinolones in patients who have risk factors for penicillin resistance or who have documented infections caused by S. pneumoniae with an MIC of penicillin of у4 mg/mL [17] [18] [19] . Identification of a subgroup of patients with pneumococcal bacteremia at low risk of having high-level penicillin resistance would allow clinicians to initiate empirical therapy with fluoroquinolone-sparing regimens (e.g., b-lactams and/or macrolides or tetracyclines). This would theoretically delay the emergence of fluoroquinolone resistance in S. pneumoniae [11] [12] [13] [14] [15] [16] . The main purpose of our study was to define a subgroup of patients at low risk of having bacteremia with a high-level penicillin-nonsusceptible pneumococcal isolate. We used the 3 independent variables associated with PNSP bacteremia (previous b-lactam use, previous stay in a risk area, and previous upper or lower respiratory tract infection) to create a clinical predictive index. Among 153 patients who had none of these 3 risk factors, only 1 (0.7%) had PNSP bacteremia. Among 150 patients who had у1 risk factor, 32 (21%) had PNSP bacteremia. The model is an excellent screening tool for patients with suspected penicillin resistance, as shown by its sensitivity (97%), negative predictive value (99%), and negative likelihood ratio (0.05). These 3 risk factors are easily available to the clinician who is evaluating the patient's medical history and medical records at the bedside.
All 3 variables are biologically plausible. Jabes et al. [28] described the penicillin-binding proteins of 160 clinical isolates of pneumococci with a wide range of MICs of penicillin. Among isolates with reduced penicillin susceptibility, penicillinbinding proteins 1A, 2A, and 2B each showed stepwise decreases in their affinities to penicillin, which correlated with increasing levels of antibiotic resistance. Exposure of penicillin-susceptible isolates to increasing concentrations of b-lactams in vitro results in a stepwise increase in the MICs of penicillin [29] . Previous antibiotic use, especially use of b-lactams, has been shown to be related to pneumococcal penicillin resistance in many studies [30] [31] [32] [33] . Both the duration and class of antibiotic exposure are important predictors of penicillin resistance [33] . Horizontal transfer among pneumococcal carriers, especially in crowded living conditions, represents another important mechanism of local and supraregional spread of penicillin-nonsusceptible clones. Day care centers, nursing homes, and prisons facilitate their interchange as a result of crowded conditions [34, 35] . Previous pneumonia has also previously been described as a risk factor for penicillin resistance in pneumococci [31] .
Our study is the first to identify a low-risk subgroup for high-level PNSP. Because intermediate-level penicillin resistance has not been associated with an adverse clinical outcome but high-level resistance affects morbidity and mortality, our model was designed to estimate the likelihood of high-level penicillin-nonsusceptible pneumococcal bacteremia. If validated in additional studies, it will allow the clinician to limit the use of extended-spectrum antibiotics, such as the newer fluoroquinolones, to patients who have у1 of the 3 independent risk factors. Second, we have included all patients with pneumococcal bacteremia at 4 hospitals that serve different populations (indigent, private, and veterans). This will result in a more generalizable model that will be easier to validate in other geographical areas. Third, the outcome variable (PNSP) has clear definitions, as stated by the NCCLS [22] ; the identification of PNSP strains in different microbiology laboratories follows the same protocol.
There were limitations to our study. First, the retrospective design of the study raises the possibility of detection bias in the assessment of baseline clinical variables and outcome. We tried to limit its significance by using strict exclusion criteria and a standardized extraction form for all patients. In addition, previous antibiotic exposure was assessed by reviewing both inpatient and outpatient medical records and computerized pharmacy records at the 4 hospitals. Nevertheless, it is possible that patients received antibiotics from outside providers without our recognition. Second, on the basis of our strict criteria, we excluded 144 patients with pneumococcal bacteremia during our study period; this raises the issue of selection bias. However, the excluded and included patients did not differ significantly with regard to age, sex, and presence of high-level penicillin resistance ( ; data not shown). Third, this prediction model P 1 .2 needs to be validated in another study population of patients from a different geographical area. Finally, no data were available on susceptibilities to non-b-lactam antibiotics. However, previous studies have demonstrated a high level of cross-resistance among high-level penicillin-nonsusceptible pneumococci and other antimicrobial classes (i.e., macrolides and sulfonamides) [5] . Clinicians must also recognize that our predictive model only applies to patients with confirmed pneumococcal bacteremia. For these patients, our model could have immediate use in clinical practice.
In summary, our model provides a simple and very specific estimate of the probability of high-level penicillin resistance for the individual patient with bacteremic pneumococcal infection. This could aid clinicians in making decisions on empirical antibiotic therapy. Assuming no other clinical concerns, patients at low risk of having high-level nonsusceptible pneumococcal isolates (no previous b-lactam therapy, stay in risk area, or respiratory tract infection) could begin a fluoroquinolonesparing regimen. Judicious use of the new fluoroquinolones could delay the emergence of fluoroquinolone-resistant pneumococci in the future.
